

The circulating concentration and 24-h urine excretion of magnesium (Mg) dose- and time-dependently respond to oral Mg supplementation in a meta-analysis of randomized controlled trials

Xi Zhang,¹ Liana C. Del Gobbo,² Adela Hruby,³ Andrea Rosanoff,⁴ Ka He,⁵ Qi Dai,⁶ Rebecca B. Costello,⁴ Wen Zhang,⁷ Yiqing Song¹

Affiliations:

1. Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis, IN, USA.
2. Department of Medicine, Division of Cardiovascular Medicine, Stanford University, Stanford, CA, USA.
3. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
4. Center for Magnesium Education and Research. Pahoia, HI, USA.
5. Department of Epidemiology and Biostatistics, School of Public Health, Indiana University, Bloomington, IN, USA.
6. Division of Epidemiology, Vanderbilt Ingram Cancer Center; and Department of Veterans Affairs, Tennessee Valley Healthcare System, Geriatric, Research, Education and Clinical Center, Nashville, TN, USA.
7. Department of Epidemiology, School of Medicine, Fukushima Medical University, Fukushima, Japan.

Correspondence to Yiqing Song, MD, ScD

Department of Epidemiology

Richard M. Fairbanks School of Public Health, Indiana University

1050 Wishard Blvd, RG 5116, Indianapolis, IN 46202-2872

Tel: 317-274-3833; Fax: 317-274-3443

E-mail: yiqsong@iu.edu

Funding: This study was supported by the Indiana University Health-Indiana University School of Medicine Strategic Research Initiative Grant (Drs. X Zhang and Y Song).

Running title: Magnesium Biomarkers in RCTs

Abbreviations used: AHRQ, Agency for Healthcare Research & Quality; CI, confidential interval; DGAC, Dietary Guidelines Advisory Committee Report; DRIs, dietary reference intakes; EAR, estimated average requirement; IV, intravenous; Mg, magnesium; PRA, plasma renin activity; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; PTH, Parathyroid hormone; RCTs, randomized controlled trials; SD, standard deviation; SMDs, Standardized mean differences; WMDs, weighted mean differences.

Word count: 6,164; **Table:** 1; **Figure:** 1-5; Reference: 38; Supplemental Table 1 and Supplemental Figure 1.

Authors' last names: Zhang X, Del Gobbo LC, Hruby A, Rosanoff A, He K, Dai Q, Costello RB, Zhang W, and Song Y.

Interest declaration: All other authors, including Xi Zhang, Liana C. Del Gobbo, Adela Hruby, Andrea Rosanoff, Ka He, Qi Dai, Wen Zhang, and Yiqing Song, declared no conflicts of interest.

ABSTRACT

Background: Accurate determination of Mg status is important for improving nutritional assessment and clinical risk stratification.

Objective: We aimed to quantify the overall responsiveness of Mg biomarkers to oral Mg supplementation among adults without severe diseases and their dose- and time-responses using available data from randomized controlled trials (RCTs).

Methods: We identified 48 Mg supplementation trials ($n=2,131$) through searches of MEDLINE and the Cochrane Library up to November 2014. Random-effects meta-analysis was used to estimate weighted mean differences of biomarker concentrations between intervention and placebo groups. Restricted cubic splines was used to determine the dose- and time-responses of Mg biomarkers to supplementation.

Results: Among the 35 biomarkers assessed, serum, plasma, and urine Mg were most commonly measured. Elemental Mg supplementation doses ranged from 197 to 994 mg/d. Trails ranged from 3 wk-5 y (median: 12 wk). Mg supplementation significantly elevated circulating Mg by 0.04 mmol/L (95% CI: 0.02, 0.06) and 24-h urine Mg excretion by 1.52 mmol/24h (95% CI: 1.20, 1.83) as compared with placebo. Circulating Mg concentrations and 24-h urine Mg excretion responded to Mg supplementation in a dose- and time-dependent manner, gradually reaching a steady state at doses of 300 mg/d and 400 mg/d, or after approximately 20 wk and 40 wk, respectively (all P -nonlinearity ≤ 0.001). The higher the circulating Mg concentration at baseline, the lower the responsiveness of circulating Mg to supplementation, and the higher the urinary excretion (all P -linearity < 0.05). In addition, RBC Mg, fecal Mg, and urine calcium were significantly elevated by Mg supplementation compared to placebo (all P -values < 0.05), but

there is insufficient evidence to determine their responses to increasing Mg doses.

Conclusions: This meta-analysis of RCTs demonstrated significant dose- and time-responses of circulating Mg concentration and 24-h urine Mg excretion to oral Mg supplementation.

Keywords: Mg status, Mg biomarkers, circulating and urine Mg, meta-analysis, randomized controlled trial.

INTRODUCTION

Magnesium (Mg) is an essential cofactor in hundreds of enzymatic reactions in the human body (1). Mg deficiency or insufficiency, as defined by low circulating Mg concentrations, have been associated with a variety of chronic diseases, especially cardiometabolic diseases (2-4). Mg is found in whole grains, green leafy vegetables, legumes, and nuts (2), but is substantially lost during food refining and processing (3, 4). Mg intake is suboptimal in the US general population (5, 6), particularly among adolescent females, adult females, and the elderly; it is estimated that 70% of the elderly American population has a total Mg intake below the estimated average requirement (EAR) (7). Mg is currently included in the list of shortfall nutrients in the 2015 Dietary Guidelines Advisory Committee Report (DGAC) (8).

Accurate assessment of Mg status is crucial for clinical evaluation of Mg deficiency and associated health endpoints (9). Although accumulating epidemiological evidence suggests significant associations between low circulating (serum/plasma) Mg concentrations or urinary Mg excretion and cardiometabolic diseases (10, 11), it remains unclear whether and to what extent measurements of circulating or urine Mg concentrations are modifiable. Further, the effects of Mg supplementation on related nutritional biomarkers, such as calcium (Ca^{2+}) and parathyroid hormone (PTH) is unclear.

To comprehensively assess the responsiveness of Mg biomarkers and Mg-related biomarkers to oral Mg supplementation, we conducted a meta-analysis of randomized controlled trials

¹ AHRQ: Agency for Healthcare Research & Quality; Ca: Calcium; CI: Confidence Interval; CVD: Cardiovascular Disease; DGAC: Dietary Guidelines Advisory Committee Report; DRIs: Dietary Reference Intakes; EAR: Estimated Average Requirement; IV: Intravenous; Mg: Magnesium; MeSH: Medical Subject Headings; PTH: Parathyroid Hormone; PRA: Plasma Renin Activity; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RCTs: Randomized Controlled Trials; S/WMD: Standardized/Weighted Mean Difference; SD: Standard Deviation; 25(OH)D: 25-hydroxyvitamin D.

(RCTs), to assess their dose- and time-responses to Mg supplementation. In addition, we explored potential sources of between-study heterogeneity by pre-specified factors that may influence Mg status responsiveness, such as age, sex, ethnicities, baseline Mg status, cardiometabolic health status (diabetes, hypertension, or cardiovascular disease), Mg formulation, trial sample size, and quality.

METHODS

Search strategy

We followed PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines for meta-analyses of RCTs (12). Searches were conducted in MEDLINE and the Cochrane Library up to November 1, 2014. The words of “magnesium”, “Mg”, “supplementation”, “supplement”, “intervention”, “depletion”, “randomized controlled trial”, “randomized clinical trial”, “randomized trial”, “controlled trial”, and “clinical trial” were used in article texts and MeSH (Medical Subject Headings) terms in searches. We also manually searched additional eligible trials from the references of relevant original or review papers. All searches were limited to articles published in English.

Selection criteria

We included RCTs of oral Mg supplementation in adults, which evaluated Mg biomarkers at baseline and after the intervention. Exclusion criteria are listed as follows: 1) studies involving pregnant or lactating women; 2) non-randomized, open-label, or uncontrolled studies; and 3) studies of patients with malignancy, severe anemia, severe infectious disease, severe liver or renal diseases, and other severe illnesses, as these disease conditions might directly or indirectly affect normal Mg metabolism. Studies that used combination supplements with Mg in the

intervention group were eligible only if the same combined supplements without Mg were included in the control group. Trials comparing multiple micronutrients containing Mg to placebo/blank controls were ineligible.

Study selection

Two authors (X Zhang and Y Song) independently examined the title and abstract of each article to remove irrelevant and duplicated results first. Then, any articles deemed potentially eligible underwent a full-text review and their eligibilities were assessed based on the same inclusion and exclusion criteria. Any discrepancies were resolved through discussion.

Data extraction

From each included study, we extracted available data on first author's name, year of publication and country, sex, mean age or age range, number of participants, comorbidities, combination therapy, baseline dietary Mg level, study design, trial duration, formulation and dose of Mg supplements, types of Mg biomarkers assessed, and means and standard deviations (SD) of biomarkers in both Mg and control groups before and after supplementation.

One study compared multiple dose intervention groups with a single placebo or control group. To avoid correlation error and multiple comparisons, we divided the shared control group into 2 independent small groups with the means and SDs weighted by the corresponding sample sizes of intervention groups (13). If repeated measures of Mg biomarker at several time points were reported in a single trial, the values at the end of the study were selected for overall meta-analysis; however, both were included in subgroup analyses when estimates were stratified into separate groups by pre-specified factors.

Assessment of risk of bias

Trial quality was evaluated according to the Agency for Healthcare Research & Quality (AHRQ) criteria for quality assessment of RCTs (14, 15). The evaluation criteria include adequate sequence generation for randomization, allocation concealment, blinding of outcomes assessors, similarity of groups at baseline, selective reporting, incomplete outcome data, and description of losses and exclusions. Each study was judged to be of either high, low, or unclear risk for each criterion. In order to evaluate the potential confounding effect from trial quality, we also calculated a 5-item Jadad Score (16, 17) and rated each individual trial as being of either low (< 4) or high quality (≥ 4).

Statistical methods

The primary measures of interest were changes in the concentrations of Mg biomarkers in response to Mg supplementation. The secondary outcomes were changes in the concentrations of indirect but Mg status-related biomarkers, including serum calcium, potassium, PTH, and vitamin D, if available. To evaluate the overall responsiveness of biomarkers, we compared the mean changes between treatment and placebo groups, calculated as weighted mean differences (WMDs) and 95% CIs using a random-effects meta-analysis model (18). Standardized mean differences (SMDs) were estimated only when it was difficult to standardize the measure scales of data from individual studies. We calculated the WMDs for serum and plasma Mg concentrations separately, and found similar magnitude and patterns of these responses. Thus, we analyzed and presented circulating Mg concentrations by pooling the results of serum and plasma Mg concentrations from independent trials. Urine Mg was measured as 24-h urine Mg excretion (mmol/24h) in this study. We examined between-study heterogeneity by Q test and I^2 statistics, with $I^2 \geq 75\%$ indicating high heterogeneity.

To explore potential sources of heterogeneity and assess robustness of the results, we

conducted subgroup analyses stratified by age, sex, ethnicities, baseline Mg status, cardiometabolic health status (diabetes, hypertension, or cardiovascular disease), Mg formulation, trial sample size, and quality. Additionally, sensitivity analyses were conducted by removing one study at a time to check if a single study substantially influenced the summary measure of each meta-analysis. We examined possible publication bias by visual inspection of funnel plots and formal tests, including Begg's adjusted rank correlation test and Egger's regression asymmetry test (19, 20).

Restricted cubic spline regression analyses were performed to assess the dose- and time-responses relations of biomarkers to Mg supplementation. For each study, we calculated restricted cubic splines with three fixed knots at 10%, 50%, and 90% percentiles based on the overall distributions of doses and trial durations of all included studies. Then we combined the estimates to depict dose- and time-dependent linear or nonlinear relations of Mg biomarker responsiveness to Mg supplementation (21, 22).

A two-tailed $P < 0.05$ was considered statistically significant. Stata (Version 13; StataCorp, College Station, TX) was used for all statistical analyses.

RESULTS

Our systematic search initially identified 1,766 articles (**Figure 1**). Among them, 38 articles met inclusion criteria, consisting of 48 RCTs assessing 35 Mg biomarkers (**Supplemental Table 1**). A total of 2,131 adult participants were studied: 1,105 in the randomly assigned Mg supplement groups and 1,026 in the placebo groups. Trial durations ranged from 3 wk to 5 y (median: 12 wk). Participants had a median age of 47 y (range: 17–85 y); 56% of participants were women, and 58.4% were considered healthy. Doses of Mg supplements varied widely from 197 to 994 mg/d elemental Mg (median: 360 mg/d). Two major types of Mg salts, organic (50%

trials) and inorganic Mg salts, were administered based on 9 Mg formulations. Among them, the six organic formulations were Mg orotate, Mg citrate, Mg aspartate, Mg gluconate, Mg pidolate, and Mg lactate; and the three inorganic formulations were Mg(OH)₂, MgO, and MgCl₂.

Of 35 identified biomarkers, serum and plasma Mg were most commonly used (41 trials), followed by 24-h urine Mg (24 trials), red blood cell Mg (9 trials), and ionized Mg (5 trials). Only a few articles evaluated Mg status in other compartments, such as muscle, intracellular, saliva, hair, feces, and brain tissue (**Figure 1**). Additionally, 16 publications provided data on biomarkers indirectly related to Mg status, including calcium, potassium, and sodium concentrations in serum/plasma or urine, serum Ca/Mg ratio, PTH, and plasma renin activity (PRA).

Circulating Mg concentrations

Circulating Mg (serum or plasma) was most common biomarker assayed (41 trials), accounting for 87% of eligible articles (941 participants in treatment and 953 in control arms). After Mg supplementation at a median dose of 365 mg/d (range: 197–994 mg/d) for 12 wk (range: 3 wk–5 y), circulating Mg concentrations were significantly elevated in the treatment groups in comparison to the placebo groups (WMD: 0.04 mmol/L; 95% CI: 0.02, 0.06) (**Table 1**).

Among participants receiving Mg supplementation with a median dose of 365 mg/d for a median duration of 12 wk, the overall population distribution shifted from a mean circulating Mg concentrations of 0.78 mmol/L at baseline to 0.83 mmol/L at post-treatment (**Figure 2A**).

24-h Urine Mg excretion

Approximately half (55%) of the 24 included trials examined 24-h urine Mg excretion (645

participants in treatment and 716 in control arms). After supplementing with a median dose of 480 mg/d (range: 200–994 mg/d) for a median duration of 3 mo (range: 1 mo–1 y), 24-h urine Mg excretion was significantly elevated (WMD: 1.52 mmol/24h; 95% CI: 1.20, 1.83) compared to the placebo groups (**Table 1**). The mean urine Mg excretion in the treatment groups significantly increased by 32% (WMD: 1.24 mmol/24h; 95% CI: 0.94, 1.54) after treatment compared to baseline (**Figure 2B**).

RBC Mg

Nine trials examined RBC Mg, with 213 participants receiving Mg supplements and 208 receiving placebos. After Mg supplementation with a median dose of 320 mg/d (range: 250–600 mg/d) for a median duration of 2 mo (range: 3 wk–5 y), RBC Mg was significantly higher in the treatment groups than placebo groups (WMD: 0.12 mmol/L; 95% CI: 0.03, 0.20) (**Table 1**). A similar dose of 300 mg/d was used in all these 9 trials, which could not allow us to examine the dose-response relationship for RBC Mg.

Ionized Mg

Only 5 trials assessed ionized (intracellular) Mg; 3 in serum, 1 in plasma, and 1 in whole blood. Two trials evaluated ionized Mg in muscles. Overall, circulating ionized Mg concentrations were not significantly increased among 111 participants who received Mg supplements at a median dose of 320 mg/d (range: 197–360 mg/d) for 2 mo (range: 1–6.5 mo) compared to 107 participants who received placebos (WMD: 0.004 mmol/L, $P=0.58$). Two individual studies measured muscle ionized Mg; no significant differences between treatment and placebo groups were observed (23, 24).

Other Mg biomarkers in blood, urine, or other specimens

As only a few trials examined intravenous (IV) Mg load, Mg balance, Mg retention, and mononuclear Mg, insufficient data were available for a meta-analysis of these biomarkers (**Table 1**).

Mg in other tissues such as intracellular (4 trials), muscle (2 trials), feces (2 trials), hair (1 trial), saliva (1 trial), and brain tissue (1 trial) were also assessed. Among these biomarkers, only fecal Mg concentrations were significantly elevated compared with placebo group after supplementation; the SMD based on 2 trials was 3.57 (95% CI: 1.59, 5.56) (**Table 1**). In addition, two trials evaluated muscle Mg concentrations, but no significant changes in this biomarker were observed (WMD: -0.20 mmol/L; 95% CI: -0.50, 0.10).

Other Mg status-related biomarkers

Among circulating and urine calcium, sodium, and potassium (**Table 1**), only urine calcium excretion was significantly increased by Mg supplementation to 0.40 mmol/24h (95% CI: 0.08, 0.72; $n=5$ trials). The median Mg dose administered was 360 mg/d (range: 320–485 mg/d) for 16 wk (range: 7 wk–6 mo). Three trials also evaluated the changes of PRA and plasma PTH; no significant differences between intervention and placebo arms was observed.

For all above analyses, no significant publication bias was detected by either Egger's test or Begg's test (all P -values >0.05).

Dose- and time-dependent responses of circulating and urine Mg concentrations

Figure 3 (A & B) shows nonlinear dose- and time-responses of circulating Mg to Mg supplementation (all P - nonlinearity <0.0001). Based on data from 41 eligible trials, circulating Mg concentrations appeared to increase immediately after supplementation and gradually reached a plateau concentration at a dose of approximately 300 mg/d (range: 300-994mg/d) and

at a duration of 20 wk (range: 20-52 wk).

As shown in **Figure 3 (C & D)**, urine Mg excretion increased during the first 5 wk of supplementation, and then slowly reached a maximal steady-state at a dose of approximately 400 mg/d elemental Mg, and after about 40 wk.

Heterogeneity

Between-study heterogeneity was high for circulating Mg, RBC Mg, urine Mg, and ionized Mg; all *P*-values from *Q*-tests were <0.0001 (all $I^2 > 80\%$) (**Table 1**). Sensitivity analysis showed that the overall results were robust and no single study affected the meta-analytic estimate by more than 5%.

Although no significant heterogeneity was observed by specific supplement formulation (**Figure 4**), circulating Mg concentrations in response to inorganic Mg salt were 4 times higher than the response to organic Mg salt (*P*-interaction=0.006). The WMD of circulating Mg for inorganic and organic was 0.07 mmol/L (95% CI: 0.03, 0.10) and 0.015 mmol/L (95% CI: 0.002, 0.029), respectively. Additionally, a larger WMD for circulating Mg was observed in the ≥ 65 y subgroup than <65 y subgroup, although the difference was not statistically significant.

To examine the relation between baseline Mg status and circulating and urine Mg responses, we stratified all eligible trials into four subgroups by baseline circulating Mg concentrations (< 0.77 , $0.77-0.79$, $0.80-0.86$, and ≥ 0.87 mmol/L) and four subgroups by baseline 24-h urine Mg excretion (< 3.15 , $3.15-3.63$, $3.64-4.62$, and ≥ 4.63 mmol/24h). We found that high baseline circulating Mg concentrations were associated with less of an increase in circulating Mg by supplementation, and greater 24-h urinary Mg excretion (**Figure 5 A & C**) (both *P*-linearity <0.05). Baseline 24-h urine Mg excretion was positively and significantly associated with changes in urine Mg excretion (*P*-linearity=0.03) (**Figure 5 D**), but not changes in circulating

Mg concentrations in response to supplementation ($P=0.95$) (**Figure 5 B**).

Quality of trials

Due to insufficient information in the descriptions of included articles, only 21.1% seemed to have adequate sequence generation and 7.9% had low risk of bias in allocation concealment (**Supplemental Figure 1**). Sample sizes of included trials were small, ranging from 13 to 155 participants. High quality studies accounted for 71.0% of the included trials. However, neither study quality nor sample size substantially affected biomarker responses to Mg supplements (**Figure 4**).

DISCUSSION

In this meta-analysis of 48 RCTs examining a total of 35 Mg biomarkers, circulating and urine Mg, the most frequently measured biomarkers, were significantly increased by Mg supplementation in a dose- and time-response manner. Effect modification by baseline circulating Mg concentrations, and inorganic vs. organic formulation of Mg supplement type was observed. This investigation provides the most comprehensive estimates to-date of the relationships between Mg biomarkers and Mg supplementation, and for the first time to our knowledge, the time-response of Mg biomarkers to supplementation in generally healthy populations.

In our meta-analysis, an elevation of 6% (0.05 mmol/L) in circulating Mg and of 32% (1.29 mmol/24h) in urine Mg was observed in response to varied doses of oral Mg supplementation. Assuming a conservative cut-off level of serum Mg < 0.70 (or < 0.75 mmol/L) for defining Mg insufficiency (6), Mg supplementation substantially reduced the prevalence of insufficiency from 26 to 2.1%, (or from 39 to 12%). Our analysis of 48 trials builds on and expands on findings of an earlier systematic review (22 trials) in which Mg supplementation increased circulating Mg

concentrations by 0.03 mmol/L and urinary Mg excretion by 1.82 mmol/24h (25). Altogether, this evidence suggests that Mg supplementation may reduce the risk of cardiovascular diseases (CVD), as previous meta-analyses of prospective studies have found that higher concentrations of circulating Mg are associated with lower CVD risk (10, 11). In addition, low 24-h urine Mg excretion was independently associated with a 40% higher risk of CVD incidence in a prospective population-based study (26).

Our novel dose- and time-response analyses revealed a maximal response of circulating Mg to oral supplementation at a dose ≥ 300 mg/d, and showed that at least 20 wk of Mg supplementation are required to achieve this steady-state concentration. Consistent with these findings, previous pharmacokinetic research indicated a relatively slow process of Mg equilibrium in humans with a half-life of >1000 h (≈ 6 wk) (27). Urine Mg achieved its highest levels at doses of ≥ 400 mg/d, and required a longer duration of supplementation, 30–40 wk. Given the observed dose- and time-dependent responses, circulating and urine Mg may be clinically useful biomarkers underlying Mg homeostasis in the human body.

Our analysis revealed important heterogeneity by baseline circulating Mg concentrations: we observed that high baseline circulating Mg concentrations were associated with less of an increase in circulating Mg by Mg supplementation, and greater 24-h urinary Mg excretion. If baseline circulating Mg concentrations ≥ 0.87 mmol/L, a concentration level with the normal range, Mg supplementation did not result in significant changes in circulating Mg concentrations, but substantial increase in urine Mg excretion. In fact, minimal to no responsiveness of circulating Mg concentrations and elevated urinary Mg excretion to Mg supplementation was observed among participants with normal Mg status, as objectively assessed by the gold standard Mg loading test (28, 29). Taken together, the results support the notion that circulating Mg and

24-h urinary excretion Mg may provide meaningful information about underlying Mg status, and provide new evidence that circulating Mg concentrations above currently defined clinical thresholds for hypomagnesemia may be appropriate for defining sufficient Mg status.

Our heterogeneity analyses also revealed, for the first time, that circulating Mg concentrations exhibit a significantly greater increase to inorganic Mg supplements than to organic supplements. The formulation of Mg is a key factor in its bioavailability. Previous work showed that organic Mg salts were more bioavailable than inorganic Mg salts supplements in animals (30) due to the limited solubility of inorganic Mg in the intestine (31, 32), a finding that seems to be contrary to our results. However, circulating concentrations of Mg in the inorganic supplement groups were lower than in the organic supplement groups, which may partially explain these findings. Our additional comparisons for different chemical formulations of oral Mg supplements, including Mg(OH)₂, MgO, MgCl₂, citrate, aspartate, and pidolate Mg, did not show significantly different responses of circulating Mg concentrations and urine Mg excretion. These findings are consistent with evidence from bioavailability experiments, showing that various Mg salts were nearly equivalent in their ability to increase circulating and urine Mg (30, 33, 34).

Recently, ionized Mg has been proposed as a potentially useful biomarker of the biologically active portion of Mg in human (35). The limited numbers and small sample sizes of included trials investigating ionized Mg might partially explain the null pooled effect of Mg supplementation on ionized Mg. Also, vastly different assay methods and specimens used in trials may lead to large variance in the measurements of ionized Mg, making these estimates potentially inappropriate for meta-analysis.

Other tissue Mg concentrations such as muscle, saliva, hair, fecal, and brain tissues were also

reported in some trials. However, sensitivity of these biomarkers to Mg supplementation requires more data. Co-existence of secondary electrolyte abnormalities may play a key role in the clinical features of Mg depletion (36). For instance, calcium, potassium, and sodium in blood and urine were frequently assessed, and urine calcium concentrations appear to be more sensitive to Mg supplementation than others based on the present analysis. Despite some biological evidence suggesting that hypomagnesemia may interfere with the hypocalcaemia-induced PTH release (37, 38), our analysis based on 3 RCTs showed that Mg supplementation did not significantly affect PTH concentrations.

Our meta-analysis has several strengths. Our quantitative assessment was based on data from RCTs largely of high-quality, which excluded open-label and one-arm trials, thereby minimizing selection bias and other biases. Our comprehensive search strategy make it unlikely that any major published trials were missed. The quality of all trials were formally evaluated by AHRQ criteria and Jada score to assess the influence of overall trial quality on the results. We also systematically reviewed both direct and indirect Mg-status related biomarkers, and addressed dose- and time-response of Mg biomarkers to Mg supplementation for the first time.

Several limitations warrant consideration. First, although a large number of randomized trials were included in our meta-analysis, few trials for biomarkers other than circulating and urine Mg was available, such as ionized Mg, and Mg in muscle, saliva and other tissues. Second, the presence of substantial between-study heterogeneity in the main meta-analyses could add uncertainty to estimates. However, we conducted several subgroup analyses stratified by many pre-specified factors, such as baseline Mg status, and organic vs. inorganic formulation, which contributed to significant heterogeneity of results. Third, trials with larger sample sizes and longer durations are clearly lacking. Fourth, influence by inadequate sequence generation and

allocation concealment as well as compliance could not be assessed due to a lack of relevant information in most of included RCTs. Finally, as in any meta-analysis of published results, publication bias is possible, although we did not find any evidence of publication bias based on Egger's or Begg's tests.

In conclusion, this meta-analysis of 48 RCTs showed that circulating Mg concentrations and 24-h urine Mg excretion significantly responded to oral Mg supplementation in a dose- and time-dependent manner. High baseline circulating Mg concentrations were associated with less or no changes in circulating Mg concentrations and a greater response of urine Mg excretion by Mg supplementation, consistent with gold-standard Mg loading test findings. Altogether, these findings support the notion that circulating Mg and 24-h urinary excretion Mg may provide meaningful information about underlying Mg status, and provide new evidence that a relatively high threshold level of circulating Mg concentrations, well above currently defined clinical thresholds for hypomagnesemia may be appropriate for defining sufficient Mg status. Our findings also directly inform the design of future Mg supplementation trials. Future well-designed, adequately powered RCTs of Mg supplementation on intermediate and clinical endpoints are warranted to elucidate the potential role of Mg biomarkers for clinical risk assessment and population health.

ACKNOWLEDGEMENTS

The authors' contributions to manuscript were as follows — XZ and YS: designed and conducted the research; XZ: analyzed data and had primary responsibility for the final content of the manuscript; and all authors, including LD, AH, AR, KH, QD, RC, WZ, wrote the manuscript, and read and approved the final manuscript. All authors have read and approved the final manuscript.

The project described was supported by the Indiana University Health–Indiana University School of Medicine Strategic Research Initiative (Drs. X Zhang and Y Song).

REFERENCES

1. Saris NE, Mervaala E, Karppanen H, Khawaja JA, Lewenstam A. Magnesium. An update on physiological, clinical and analytical aspects. *Clin Chim Acta* 2000;294(1-2):1-26.
2. Cleveland LE, Goldman JD, Borrud LG. Data tables: Results from USDA's 1994 continuing survey of food intakes by individuals and 1994 diet and health knowledge survey. Beltsville, MD.: Agricultural Research Service, U.S. Department of Agriculture., 1994.
3. Groff JL, Gropper SS. Macrominerals. In: *Advanced Nutrition and Human metabolism*. 3rd ed: California:Wadsworth, 2000, 371-400.
4. Vaquero MP. Magnesium and trace elements in the elderly: intake, status and recommendations. *J Nutr health aging* 2002;6(2):147-53.
5. Marier JR. Dietary magnesium and drinking water: effects on human health status. In: Sigel H, Sigel A (eds). *Metal Ions in Biological Systems*: New York, NY: Marcel Dekker, Inc., 1990.
6. Lowenstein FW, Stanton MF. Serum magnesium levels in the United States, 1971-1974. *J Am Coll Nutr* 1986;5(4):399-414.
7. Moshfegh A GJ, Cleveland LE. What We Eat in America, NHANES 2001-2002: Usual Nutrient Intakes from Food Compared to Dietary Reference Intakes. U.S. Department of Agriculture, Agricultural Research Service 2005.
8. 2015. DGAC. Scientific Report of the 2015 Dietary Guidelines Advisory Committee. Advisory Report to the Secretary of Health and Human Services and the Secretary of Agriculture. Department of Agriculture, Agricultural Research Service, Washington, DC.
9. Elin RJ. Magnesium metabolism in health and disease. *Disease-a-month : DM* 1988;34(4):161-218.
10. Del Gobbo LC, Imamura F, Wu JH, de Oliveira Otto MC, Chiuve SE, Mozaffarian D. Circulating and dietary magnesium and risk of cardiovascular disease: a systematic review and meta-analysis of prospective studies. *Am J Clin Nutr* 2013;98(1):160-73. doi: 10.3945/ajcn.112.053132.
11. Qu X, Jin F, Hao Y, Li H, Tang T, Wang H, Yan W, Dai K. Magnesium and the risk of cardiovascular events: a meta-analysis of prospective cohort studies. *PloS one* 2013;8(3):e57720. doi: 10.1371/journal.pone.0057720.
12. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. *Ann Intern Med* 2009;151(4):W65-W94.
13. JPT H. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions*. Version 5.1.0 [updated March 2011]. <http://www.cochrane-handbook.org>. Accessed February 3, 2011. 2011.
14. *Methods Guide for Effectiveness and Comparative Effectiveness Reviews*. Agency for Healthcare Research and Quality. <http://effectivehealthcareahrq.gov/ehc/products/60/318/CER-Methods-Guide-140109pdf> Accessed April 21, 2014.
15. Viswanathan M, Ansari MT, Berkman ND, Chang S, Hartling L, McPheeters M, Santaguida PL, Shamliyan T, Singh K, Tsertsvadze A, et al. Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions. Edtion ed. *Methods Guide for Effectiveness and Comparative Effectiveness Reviews*. Rockville (MD), 2008.
16. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. *BMJ* 2001;323(7303):42-6.
17. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? *Control Clin Trials* 1996;17(1):1-12. doi: Doi 10.1016/0197-2456(95)00134-4.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;7(3):177-88.
19. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994;50(4):1088-101.

20. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315(7109):629-34.
21. Orsini N, S. Greenland. A procedure to tabulate and plot results after flexible modeling of a quantitative covariate. *Stata Journal* 2011;11:29.
22. Orsini N, Li R, Wolk A, Khudyakov P, Spiegelman D. Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. *Am J Epidemiol* 2012;175(1):66-73. doi: 10.1093/aje/kwr265.
23. Weller E, Bachert P, Meinck HM, Friedmann B, Bartsch P, Mairbaurl H. Lack of effect of oral Mg-supplementation on Mg in serum, blood cells, and calf muscle. *Med Sci Sports Exerc* 1998;30(11):1584-91.
24. Wary C, Brillault-Salvat C, Bloch G, Leroy-Willig A, Roumenov D, Grognet JM, Leclerc JH, Carlier PG. Effect of chronic magnesium supplementation on magnesium distribution in healthy volunteers evaluated by ³¹P-NMRS and ion selective electrodes. *Br J Clin pharmacol* 1999;48(5):655-62.
25. Witkowski M, Hubert J, Mazur A. Methods of assessment of magnesium status in humans: a systematic review. *Magnes Res* 2011;24(4):163-80. doi: 10.1684/mrh.2011.0292.
26. Joosten MM, Gansevoort RT, Mukamal KJ, van der Harst P, Geleijnse JM, Feskens EJ, Navis G, Bakker SJ, Group PS. Urinary and plasma magnesium and risk of ischemic heart disease. *Am J Clin Nutr* 2013;97(6):1299-306. doi: 10.3945/ajcn.112.054114.
27. Avioli LV, Berman M. Mg²⁸ kinetics in man. *J Appl Physiol* 1966;21(6):1688-94.
28. Walti MK, Walczyk T, Zimmermann MB, Fortunato G, Weber M, Spinaz GA, Hurrell RF. Urinary excretion of an intravenous Mg-26 dose as an indicator of marginal magnesium deficiency in adults. *Eur J Clin Nutr* 2006;60(2):147-54. doi: DOI 10.1038/sj.ejcn.1602278.
29. Feillet-Coudray C, Coudray C, Tressol JC, Pepin D, Mazur A, Abrams SA, Rayssiguier Y. Exchangeable magnesium pool masses in healthy women: effects of magnesium supplementation. *Am J Clin Nutr* 2002;75(1):72-8.
30. Coudray C, Rambeau M, Feillet-Coudray C, Gueux E, Tressol JC, Mazur A, Rayssiguier Y. Study of magnesium bioavailability from ten organic and inorganic Mg salts in Mg-depleted rats using a stable isotope approach. *Magnes Res* 2005;18(4):215-23.
31. Ranade VV, Somberg JC. Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans. *Am J Ther* 2001;8(5):345-57.
32. Bohn T. Dietary Factors Influencing Magnesium Absorption in Humans. *Curr Nutr Food Sci* 2008;4(1):53-72.
33. Cook DA. Availability of magnesium: balance studies in rats with various inorganic magnesium salts. *J Nutr* 1973;103(9):1365-70.
34. Borella P, Ambrosini G, Concari M, Bargellini A. Is magnesium content in erythrocytes suitable for evaluating cation retention after oral physiological supplementation in marginally magnesium-deficient subjects? *Magnes Res* 1993;6(2):149-53.
35. Altura BM. Introduction: importance of Mg in physiology and medicine and the need for ion selective electrodes. *Scand J Clin Lab Invest Suppl* 1994;217:5-9.
36. Fawcett WJ, Haxby EJ, Male DA. Magnesium: physiology and pharmacology. *Br J Anaesth* 1999;83(2):302-20.
37. Anast CS, Winnacker JL, Forte LR, Burns TW. Impaired release of parathyroid hormone in magnesium deficiency. *J Endocrinol Invest* 1976;42(4):707-17. doi: 10.1210/jcem-42-4-707.
38. Iwasaki Y, Asai M, Yoshida M, Oiso Y, Hashimoto K. Impaired parathyroid hormone response to hypocalcemic stimuli in a patient with hypomagnesemic hypocalcemia. *J Endocrinol Invest* 2007;30(6):513-6.

TABLE 1. Overall weighted mean differences (WMDs/SMDs) of Mg biomarkers (treatment versus control groups) after oral Mg supplementation in 48 RCTs

Biomarkers	<i>n</i> of studies (<i>n</i> of participants in placebo/treatment)	Pooled effect sizes, WMD (95% CI)	<i>P</i> -values for WMD/SMD	Measures of heterogeneity, <i>I</i> ² , %	<i>P</i> -values for heterogeneity ³
Mg Biomarkers					
Serum Mg, mmol/L	29 (705/683)	0.05 (0.02, 0.07)	< 0.0001	98.60	< 0.0001
Plasma Mg, mmol/L	12 (236/270)	0.03 (0.01, 0.05)	< 0.0001	85.90	< 0.0001
Serum/plasma Mg, mmol/L ¹	41 (941/953)	0.04 (0.02, 0.06)	< 0.0001	98.10	0.003
RBC Mg, mmol/L	9 (416/426)	0.12 (0.03, 0.20)	0.006	91.50	< 0.0001
Mononuclear Mg ²	4 (292/236)	0.08 (-0.22, 0.38)	0.60	0.00	0.54
Blood Ionized Mg, mmol/L	5 (214/222)	0.004 (-0.011, 0.019)	0.58	94.60	< 0.0001
24-h Urine Mg, mmol/24h	24 (1656/1527)	1.52 (1.20, 1.83)	< 0.0001	96.90	< 0.0001
Muscle Mg, mmol/100g	2 (118/118)	-0.20 (-0.50, 0.10)	0.08	35.30	0.21
Muscle Ionized Mg, mmol/L	2 (50/50)	-0.01 (-0.05, 0.03)	0.32	47.90	0.17
Intracellular Mg ²	4 (126/136)	-0.39 (-1.51, 0.72)	0.49	86.50	< 0.0001
Fecal Mg ²	2 (80/80)	3.57(1.59, 5.56)	< 0.0001	87.10	< 0.0001
Mg Status-related Markers					
Blood Ca, mmol/L	12 (560/617)	0.01 (-0.01, 0.03)	0.17	82.90	< 0.0001
Blood K, mmol/L	8 (340/385)	0.08 (-0.14, 0.31)	0.47	87.20	< 0.0001
Blood Na, mmol/L	6 (184/227)	0.13 (-0.73, 0.99)	0.76	34.80	0.18
PTH, pg/mL	3 (134/140)	1.13 (-10.4, 12.7)	0.85	84.80	0.001
PRA ²	3 (72/113)	0.03 (-0.48, 0.53)	0.91	11.40	0.32
24-h Urine Ca, mmol/24h	5 (428/334)	0.40 (0.08, 0.72)	0.02	81.30	< 0.0001
24-h Urine K, mmol/24h	7 (484/425)	2.67 (-1.16, 6.51)	0.17	52.90	0.05
24-h Urine Na, mmol/24h	7 (472/413)	2.54 (-9.80, 14.87)	0.69	77.40	< 0.0001

¹ Independent trials with either serum or plasma Mg concentrations were pooled together.

² The pooled effect was SMD because the units varied among studies.

³ *P*-values were calculated for testing the between-study heterogeneity.

Abbreviations: PTH, Parathyroid Hormone; PRA, Plasma Renin Activity; RBC, Red Blood Cell; RCT, Randomized Controlled Trial; SMD, Standard Mean Difference; WMD, Weighted Mean Difference.

FIGURES LEGENDS

FIGURE 1. Flow chart of study selection of eligible 48 RCTs for the meta-analysis.

Abbreviations: Ca: calcium; IV: intravenous; K: potassium; Mg: magnesium; Mg^{2+} : ionized Mg; Mg^{2+}/Mg : ratio of serum ionized Mg to total serum Mg; Na: sodium; PTH: Parathyroid Hormone; PRA: Plasma Renin Activity; RBC: red blood cell, RCT: randomized controlled trial.

FIGURE 2. Distributions of circulating Mg concentrations (A) and 24-h urine Mg excretion (B) among participants in the treatment groups before and after Mg supplementation.

FIGURE 3. Circulating Mg concentrations (A, B) and 24-h urine Mg excretions (C, D) in response to the doses (A, C) or durations (B, D) of Mg supplementation. The relations were fitted by using restricted cubic spline curves and the 95% CIs shown as the gray shaded regions.

FIGURE 4. Forest plots of weighted mean differences (WMDs) and their 95% confidence intervals (95% CIs) of responses of circulating Mg concentrations and 24-h urine Mg excretion to Mg supplementation compared with placebo stratified by age, sex, ethnicities, types of Mg supplements (compound formulation and salt type), cardiometabolic health status of participants, trial sample size, and quality of trials. Closed squares indicate the point estimates of WMDs from random-effects meta-analysis; horizontal bands represent the 95% CIs. $n_{\text{circulating Mg}}$: number of the included trials with available data on circulating Mg concentrations; $n_{\text{urine Mg}}$: number of trials with available data on 24-h urine Mg excretion; $P_{\text{circulating Mg}}$ and $P_{\text{urine Mg}}$: *P*-values for interactions between Mg supplementation and each of stratified factors on circulating Mg concentrations and 24-h urine Mg excretion, respectively; EP: Europeans; North A: North Americans; Latin A: Latin Americans; healthy and unhealthy status indicate participants with and without history of diabetes mellitus, cardiovascular diseases, or hypertension.

FIGURE 5. Weighted mean differences and their 95% CIs of responses of circulating Mg

concentrations (A, B) and 24-h urine Mg excretions (C, D) to Mg supplementation compared with placebo stratified by baseline circulating Mg concentrations (A, C) and urine Mg excretions (B, D).

Figure 1




Figure 2




Figure 3




Figure 4





Figure 5



Supplemental Table 1. Characteristics of trials included in the meta-analysis

Study	Age, y	Sex, %men	Formulation; Dosage; Duration	n_T/n_P ¹ , Design	Participants	Concomitant	Biomarkers	Baseline dietary Mg	Quality ² , Compliance
Zemel, 1990, USA (1)	Range: 20-69	Mixed, 86%	Mg aspartate; 40mmol/d;3 mo	7/6, Parallel	Uncomplicated mild-to-moderate essential hypertension and normal renal function	Off all antihypertensive medication for ≥ 3 mo	Serum: Ca, Mg, K, Na; 24-h urinary Mg: Ca, Mg, K, Na; Erythrocyte intracellular: Mg; PRA	NR	3, 97%
Facchinetti, 1991, Italy (2)	Range: 24-39	Women, 0%	Mg pyrrolidone carboxylic; 360mg/d;3 mo (14 d per mo)	14/14, Parallel	Premenstrual syndrome	None	Plasma, erythrocyte, lymphocytes, polymorphonuclear Mg	NR	4, NR
Desbiens, 1992, USA (3)	Range: 22-76	Mixed, 44%	MgO; 362mg/d & 724mg/d;1 mo	16/18/14, Parallel	Healthy	None	Serum Mg, Mononuclear Mg	NR	3, NR
Ferrara, 1992, Italy (4)	Range: 40-60	Mixed, 57%	Mg pidolate; 15mmol/d;6 mo	7/7, Parallel	Mild to moderate hypertension	None	Serum Na, K, Ca, and Mg; Urinary Na, K, Ca, and Mg	NR	3, NR
Bashir, 1993, USA (5)	Range: 42-73	Mixed, 48%	MgCl ₂ ; 15.8mmol/d;6 wk	21, Crossover	Stable congestive heart failure	Diuretic therapy	Serum Mg, Na, and K; Urinary Mg and K	NR	4, NR
Pulm-Wirell, 1994, Sweden (6)	Range: 20-59	Mixed, 62%	Aspartate hydrochloride; 15mmol/d;2 mo	21/18, Crossover	Untreated hypertension	Only lifestyle intervention	Serum Mg and K; Urinary Mg, K, and Na; Muscle: Mg, K	NR	4, NR
Witteman, 1994, Netherlands (7)	Range: 35-77	Women, 0%	Mg aspartate-HCl; 485 mg/d;6 mo	47/44, Parallel	Mild to moderate hypertension	Not on antihypertensive medication	Serum: Ca, Mg 24-h urinary: Ca, Mg, K, Na Plasma: PTH	T: 330 \pm 54 P: 333 \pm 80 mg/d	4, T: 91% P: 88%
Eibl, 1995, Austria (8)	Mean: 58	Mixed, 50%	Mg citrate; 365mg/d; 3 mo	18/20, Parallel	Type 2 diabetes	None	Serum Mg, Urinary Mg	NR	4, NR
Eriksson, 1995, Finland (9)	NIDDM: 43 \pm 2 IDDM: 61 \pm 2	NR	NR; 600mg/d;90 d	29 NIDDM 27 IDDM, Crossover	Non-insulin-dependent or insulin-dependent diabetes	Insulin, diabetic drug & lifestyle intervention	Plasma Mg and Urinary Mg	NR	4, NR

Online Supporting Material

Supplemental Table 1. Characteristics of trials included in the meta-analysis (Cont.)

Study	Age, y	Sex, %men	Formulation; Dosage; Duration	n_T/n_P ¹ , Design	Participants	Concomitant	Biomarkers	Baseline dietary Mg	Quality ² , Compliance
Itoh, 1996, Japan (10)	Mean: 64	Mixed, 50%	Mg(OH) ₂ ; 411gm/d women, 548mg/d men; 4 wk	23/10, Parallel	Healthy	None	Serum: Mg, K Ca, Na; Urinary Mg, Na, K, PRA	P: 222 ± 17 T: 229 ± 23 mg/d	3, NR
Sanjuliani, 1996, Brazil (11)	Range: 36-65	Mixed, 88%	MgO; 600mg/d; 6 wk	15, Crossover	Mild to moderate primary hypertension	None	RBC Na, Mg, Ca, K; Urinary Na, PRA	NR	4, NR
Costello, 1997, USA (12)	Range: 31-77	Men, 100%	Mg lactate; 249.6 mg/d; 3 mo	9/9, Parallel	Healthy	None	Serum Mg, RBC Mg, fractional urine Mg, IV load, classification of percent magnesium retention, Serum, Plasma Mg ultrafiltrates	P: 320 ± 22 T: 311 ± 18 mg/d	2, 87%
Sacks, 1997, USA (13)	Mean: 38	Women, 0%	Mg lactate; 336mg/d; 16 wk	48/102, Parallel	Healthy	None	Urinary Mg, Ca, K, Na	T: 234 ± 69 P: 238 ± 88 mg/d	3, good
de Valk, 1998, Netherlands (14)	Mean: 63	Mixed, 56%	Mg aspartate-HCl; 15mmol/d; 3 mo	25/25, Parallel	Type 2 diabetes	Insulin	Plasma Mg, Ca, Erythrocyte, Mg, Urinary Mg	NR	3, ≥80%
Lima, 1998, Brazil (15)	Range: 30-69	Mixed, 25%	MgO; 20.7 & 41.4mmol/d; 30 d	35/39/54, Parallel	Type 2 diabetes	Diet and hyperglycemic medicine	Plasma, Mononuclear, Urinary Mg	NR	3, NR
Walker, 1998, UK (16)	Range: 18-25	Women, 0%	MgO; 200mg/d; 2 mo	35/36, Crossover	Severe of premenstrual symptoms	None	Urinary Mg	NR	4, NR
Ellen, 1998, Germany (17)	Mean: 23	Mixed, 80%	MgO; 300; 3 wk	10/10, Parallel	Athletes with low-normal serum magnesium	Exercise training and diet	Serum Mg, Erythrocyte Mg, Platelete Mg, Mononuclear leukocytes Mg, Muscle Mg ²⁺	NR	3, NR
Hagg, 1999, Sweden (18)	Range: 23-56	Mixed, 46%	Mg(OH) ₂ ; 20-30 mmol/d; 12 mo	15/13, Parallel	Type I diabetes	Acting insulin medicine	Urinary Mg, Serum Mg	NR	5, NR
Warry, 1999, French (19)	Mean ± SD: 23.7±4.	Men, 100%	Mg lactate; 12mmol/d Mg and 5mg pyridoxin; 1 mo	15/15, Parallel	Healthy	None	Plasma: Mg, Mg ²⁺ ; 24h urinary Mg; RBC: Mg; muscle Mg ²⁺ & Brain tissue Mg ²⁺ ; Blood: Ca, Na, K	NR	3, good

Online Supporting Material

Supplemental Table 1. Characteristics of trials included in the meta-analysis (Cont.)

Study	Age, y	Sex, %men	Formulation; Dosage; Duration	n_T/n_P ¹ , Design	Participants	Concomitant	Biomarkers	Baseline dietary Mg	Quality ² , Compliance
Zorbas, 1999, Greece (20)	Mean: 25	Men, 100%	Mg lactate; 23mg/kg body weight; 364 d	10/10, Parallel	Healthy and hypokinetic athlete	None	Urinary Mg, fecal Mg, Serum Mg, Mg balance	hypokinetic: 627 mg/d healthy: 662 mg/d	2, NR
Walker, 2002, UK (21)	NR	Women, 0%	MgO; 200, 350, 500mg/d; 2 mo	47/40/41, Crossover	Premenstrual syndrome	None	Urinary Mg	NR	4, NR
Mooren, 2003, Germany (22)	Range: 21-30	Men, 100%	NR; 15mmol/d; 60 d	10/10, Parallel	Healthy	None	Intracellular Mg in erythrocytes, and free Mg ²⁺ in erythrocytes, extracellular Mg in serum and extracellular Mg ²⁺ in blood	NR	2, NR
Rodríguez-Morán, 2003, Mexico (23)	Mean: 57	NR	MgCl ₂ ; 2.5g/d; 16 wk	32/31, Parallel	Type 2 diabetes	Lifestyle intervention	Serum Mg, Ca, Ca/Mg	NR	5, P: 88.6% T: 91.4%
Walker, 2003, UK (24)	Mean: 25	Mixed, 35%	Mg citrate, Mg amino acid chelate, MgO; 300mg/d; 60 d	10/10, Parallel	Healthy	None	Plasma Mg, Salivary Mg	Mean: 268 mg/d	5, NR
Závaczki, 2003, Hungary (25)	Mean: 29	Men, 100%	Mg orotate; 196.8mg/d; 90 d	10/10, Parallel	Healthy	None	Serum Mg, Mg ²⁺	NR	2, NR
De Leeuw, 2004, Belgium (26)	Range: 17-67	Mixed, 56%	Mg gluconate; 300mg/d; 5 y	49/48, Parallel	Type 2 diabetes	None	Serum Mg, RBC Mg	NR	2, NR
Pokan, 2006, USA (27)	> 40	Men, 100%	Mg citrate; 365mg/d; 6 mo	28/25, Parallel	Stable coronary artery disease	Regular medication, exercise and	Intracellular Mg in sublingual epithelial cell	NR	4, NR
Rodríguez, 2008, Mexico (28)	> 60	Mixed, 48%	MgCl ₂ ; 450mg/d; 12 wk	12/11, Parallel	Type 2 diabetes and depression	None	Serum Mg	NR	5, NR
Almoznino-Sarafian, 2009, Israel (29)	Mean: 72	Mixed, 53%	Mg citrate; 300mg/d; 5 wk	16/16, Parallel	Heart failure	Insulin, statins hypoglycemic drugs, etc.	Serum Mg, intracellular Mg	NR	2, NR

Online Supporting Material


Supplemental Table 1. Characteristics of trials included in the meta-analysis (Cont.)

Study	Age, y	Sex, %men	Formulation; Dosage; Duration	N _T /N _P ¹ , Design	Participants	Concomitant	Biomarkers	Baseline dietary Mg	Quality ² , Compliance
Lee, 2009, South Korea (30)	Range: 30-60	Mixed, 50%	MgO;300mg/d;12 wk	75/80, Parallel	Overweighted	None	Serum Mg, hair Mg	NR	5, NR
Romero, 2009, Mexico (31)	Range: 40-75	Mixed, 48.1%	MgCl ₂ ;450mg/d;4 mo	42/40, Parallel	Diabetic hypertension and low serum magnesium	Captopril & lifestyle intervention	Serum: Ca, K, Na, Mg	NR	5, NR
Aydin, 2010, Turkey (32)	Mean: 53	Women, 0%	Mg citrate; 205 mg/d;30 d	10/10, Parallel	postmenopausal women	None	Serum Ca, Mg, PTH	NR	2, NR
Kazaks, 2010, USA (33)	Range: 21-55	Mixed, 44%	Mg citrate; 340mg/d;6.5 mo	28/27, Parallel	Mild to moderate asthma	Beta-agonists or inhaled corticosteroids	Serum Mg, Mg ²⁺ , erythrocyte Mg, IV Mg load	P: 281 ± 26 T: 296 ± 27 mg/d	4, T: 90.7% C: 92.5%
Nielsen, 2010, USA (34)	Range: 51-85	Mixed, 22%	Mg citrate; 320mg/d;7wk	46/49, Parallel	Poor sleep quality	None	Urinary Mg, Ca Serum: Mg, Mg ²⁺ , Mg ²⁺ /Mg, Ca RBC: Mg	NR	3, NR
Zorbas, 2010, Greece (35)	Mean ± SD: 21.5 ± 3	Men, 100%	MgCl ₂ ; 3mmol per kilogram body weight;364 d	10/10, Parallel	Healthy	None	Mg in Urine, Plasma, Muscle, Fecal	Mean: 212 mmol/d	2, NR
Chacko, 2011, USA (36)	Mean ± SD: 44 ± 13	Mixed, 71%	Mg citrate; 500mg/d;4 wk	7/7, Crossover	Healthy and overweighted	None	Serum Mg, Ca, PTH	NR	5, NR
Romero, 2011, Mexico (37)	Range: 40-65	Mixed, 59%	MgCl ₂ ; 2.5g/d;3 mo	54/52, Parallel	Healthy	None	Serum Mg	NR	5, NR
Esfanjani, 2012, Iran (38)	Range: 18-55	Mixed, 25%	MgO; 300mg/d;12 wk	33/35, 35/30, Parallel	Migraine	No analgesics	Serum Mg	NR	3, NR

¹ IV load test: intravenous load test; Mg²⁺: ionized Mg; NR: Not Report; n_T: No. of participants in treatment, n_P: No. of participants in placebo; P: Placebo; PTH: Parathyroid Hormone; PRA: Plasma Renin Activity; T: Treatment.

² Quality: The 5-point Jadad Score based on the description of randomization, double blinding and withdrawals.

Online Supporting Material



Supplemental Figure 1. Quality of identified 48 trials in the meta-analysis.

Online Supporting Material

Supplemental Reference

1. Zemel PC, Zemel MB, Urberg M, Douglas FL, Geiser R, Sowers JR. Metabolic and hemodynamic effects of magnesium supplementation in patients with essential hypertension. *Am J Clin Nutr* 1990;51(4):665-9.
2. Facchinetti F, Borella P, Sances G, Fioroni L, Nappi RE, Genazzani AR. Oral magnesium successfully relieves premenstrual mood changes. *Obstet Gynecol* 1991;78(2):177-81.
3. Desbiens NA, Marx JJ, Jr., Haas RG, Reinhart RA. Can the magnesium content of mononuclear blood cells be altered by oral magnesium supplementation? *Clin Biochem* 1992;25(4):289-92.
4. Ferrara LA, Iannuzzi R, Castaldo A, Iannuzzi A, Dello Russo A, Mancini M. Long-term magnesium supplementation in essential hypertension. *Cardiology* 1992;81(1):25-33.
5. Bashir Y, Sneddon JF, Staunton HA, Haywood GA, Simpson IA, McKenna WJ, Camm AJ. Effects of long-term oral magnesium chloride replacement in congestive heart failure secondary to coronary artery disease. *Am J Cardiol* 1993;72(15):1156-62.
6. Plum-Wirell M, Stegmayr BG, Wester PO. Nutritional magnesium supplementation does not change blood pressure nor serum or muscle potassium and magnesium in untreated hypertension. A double-blind crossover study. *Magnes Res* 1994;7(3-4):277-83.
7. Witteman JC, Grobbee DE, Derkx FH, Bouillon R, de Bruijn AM, Hofman A. Reduction of blood pressure with oral magnesium supplementation in women with mild to moderate hypertension. *Am J Clin Nutr* 1994;60(1):129-35.
8. Eibl NL, Kopp HP, Nowak HR, Schnack CJ, Hopmeier PG, Schernthaner G. Hypomagnesemia in type II diabetes: effect of a 3-month replacement therapy. *Diabetes Care* 1995;18(2):188-92.
9. Eriksson J, Kohvakka A. Magnesium and ascorbic acid supplementation in diabetes mellitus. *Ann Nutr Metab* 1995;39(4):217-23.
10. Itoh K, Kawasaki T, Nakamura M. The effects of high oral magnesium supplementation on blood pressure, serum lipids and related variables in apparently healthy Japanese subjects. *Br J Nutr* 1997;78(5):737-50.
11. Sanjuliani AF, de Abreu Fagundes VG, Francischetti EA. Effects of magnesium on blood pressure and intracellular ion levels of Brazilian hypertensive patients. *Int J Cardiol* 1996;56(2):177-83.
12. Costello RB, Moser-Veillon PB, DiBianco R. Magnesium supplementation in patients with congestive heart failure. *J Am Coll Nutr* 1997;16(1):22-31.
13. Sacks FM, Willett WC, Smith A, Brown LE, Rosner B, Moore TJ. Effect on blood pressure of potassium, calcium, and magnesium in women with low habitual intake. *Hypertension* 1998;31(1):131-8.
14. de Valk HW, Verkaaik R, van Rijn HJ, Geerdink RA, Struyvenberg A. Oral magnesium supplementation in insulin-requiring Type 2 diabetic patients. *Diabet Med* 1998;15(6):503-7.
15. de Lordes Lima M, Cruz T, Pousada JC, Rodrigues LE, Barbosa K, Cangucu V. The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes. *Diabetes Care* 1998;21(5):682-6.
16. Walker AF, De Souza MC, Vickers MF, Abeyasekera S, Collins ML, Trinca LA. Magnesium supplementation alleviates premenstrual symptoms of fluid retention. *J Womens health* 1998;7(9):1157-65.
17. Weller E, Bachert P, Meinck HM, Friedmann B, Bartsch P, Mairbaurl H. Lack of effect of oral Mg-supplementation on Mg in serum, blood cells, and calf muscle. *Med Sci Sports Exerc* 1998;30(11):1584-91.
18. Hagg E, Carlberg BC, Hillorn VS, Villumsen J. Magnesium therapy in type 1 diabetes. A double blind study concerning the effects on kidney function and serum lipid levels. *Magnes Res* 1999;12(2):123-30.

Online Supporting Material

19. Wary C, Brillault-Salvat C, Bloch G, Leroy-Willig A, Roumenov D, Grognet JM, Leclerc JH, Carlier PG. Effect of chronic magnesium supplementation on magnesium distribution in healthy volunteers evaluated by ³¹P-NMRS and ion selective electrodes. *Br J Clin Pharmacol* 1999;48(5):655-62.
20. Zorbas YG, Kakurin VJ, Afonin VB, Charapakhin KP, Denogradov SD. Magnesium supplements' effect on magnesium balance in athletes during prolonged restriction of muscular activity. *Kidney Blood Press Res* 1999;22(3):146-53. doi: 25921.
21. Walker AF, De Souza MC, Marakis G, Robinson PA, Morris AP, Bolland KM. Unexpected benefit of sorbitol placebo in Mg intervention study of premenstrual symptoms: implications for choice of placebo in RCTs. *Med Hypotheses* 2002;58(3):213-20. doi: 10.1054/mehy.2001.1407.
22. Mooren FC, Golf SW, Volker K. Effect of magnesium on granulocyte function and on the exercise induced inflammatory response. *Magnes Res* 2003;16(1):49-58.
23. Rodriguez-Moran M, Guerrero-Romero F. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. *Diabetes Care* 2003;26(4):1147-52.
24. Walker AF, Marakis G, Christie S, Byng M. Mg citrate found more bioavailable than other Mg preparations in a randomised, double-blind study. *Magnes Res* 2003;16(3):183-91.
25. Zavaczki Z, Szollosi J, Kiss SA, Koloszar S, Fejes I, Kovacs L, Pal A. Magnesium-orotate supplementation for idiopathic infertile male patients: a randomized, placebo-controlled clinical pilot study. *Magnes Res* 2003;16(2):131-6.
26. De Leeuw I, Engelen W, De Block C, Van Gaal L. Long term magnesium supplementation influences favourably the natural evolution of neuropathy in Mg-depleted type 1 diabetic patients (T1dm). *Magnes Res* 2004;17(2):109-14.
27. Pokan R, Hofmann P, von Duvillard SP, Smekal G, Wonisch M, Lettner K, Schmid P, Shechter M, Silver B, Bachl N. Oral magnesium therapy, exercise heart rate, exercise tolerance, and myocardial function in coronary artery disease patients. *Br J Sports Med* 2006;40(9):773-8. doi: 10.1136/bjism.2006.027250.
28. Barragan-Rodriguez L, Rodriguez-Moran M, Guerrero-Romero F. Efficacy and safety of oral magnesium supplementation in the treatment of depression in the elderly with type 2 diabetes: a randomized, equivalent trial. *Magnes Res* 2008;21(4):218-23.
29. Almoznino-Sarafian D, Sarafian G, Berman S, Shteinshnaider M, Tzur I, Cohen N, Gorelik O. Magnesium administration may improve heart rate variability in patients with heart failure. *Nutr Metab Cardiovasc Dis* 2009;19(9):641-5. doi: 10.1016/j.numecd.2008.12.002.
30. Lee S, Park HK, Son SP, Lee CW, Kim IJ, Kim HJ. Effects of oral magnesium supplementation on insulin sensitivity and blood pressure in normo-magneseemic nondiabetic overweight Korean adults. *Nutr Metab Cardiovasc Dis* 2009;19(11):781-8. doi: 10.1016/j.numecd.2009.01.002.
31. Guerrero-Romero F, Rodriguez-Moran M. The effect of lowering blood pressure by magnesium supplementation in diabetic hypertensive adults with low serum magnesium levels: a randomized, double-blind, placebo-controlled clinical trial. *J Hum Hypertens* 2009;23(4):245-51. doi: 10.1038/jhh.2008.129.
32. Aydin H, Deyneli O, Yavuz D, Gozu H, Mutlu N, Kaygusuz I, Akalin S. Short-term oral magnesium supplementation suppresses bone turnover in postmenopausal osteoporotic women. *Biol Trace Elem Res* 2010;133(2):136-43. doi: 10.1007/s12011-009-8416-8.
33. Kazaks AG, Uriu-Adams JY, Albertson TE, Shenoy SF, Stern JS. Effect of oral magnesium supplementation on measures of airway resistance and subjective assessment of asthma control and quality of life in men and women with mild to moderate asthma: a randomized placebo controlled trial. *J Asthma* 2010;47(1):83-92. doi: 10.3109/02770900903331127.
34. Nielsen FH, Johnson LK, Zeng H. Magnesium supplementation improves indicators of low magnesium status and inflammatory stress in adults older than 51 years with poor quality sleep.

Online Supporting Material

- Magnes Res 2010;23(4):158-68. doi: 10.1684/mrh.2010.0220.
35. Zorbas YG, Kakuris KK, Federenko YF, Deogenov VA. Utilization of magnesium during hypokinesia and magnesium supplementation in healthy subjects. *Nutrition* 2010;26(11-12):1134-8. doi: 10.1016/j.nut.2010.01.013.
 36. Chacko SA, Sul J, Song Y, Li X, LeBlanc J, You Y, Butch A, Liu S. Magnesium supplementation, metabolic and inflammatory markers, and global genomic and proteomic profiling: a randomized, double-blind, controlled, crossover trial in overweight individuals. *Am J Clin Nutr* 2011;93(2):463-73. doi: 10.3945/ajcn.110.002949.
 37. Guerrero-Romero F, Rodriguez-Moran M. Magnesium improves the beta-cell function to compensate variation of insulin sensitivity: double-blind, randomized clinical trial. *Eur J Clin Invest* 2011;41(4):405-10. doi: 10.1111/j.1365-2362.2010.02422.x.
 38. Tarighat Esfanjani A, Mahdavi R, Ebrahimi Mameghani M, Talebi M, Nikniaz Z, Safaiyan A. The effects of magnesium, L-carnitine, and concurrent magnesium-L-carnitine supplementation in migraine prophylaxis. *Biol Trace Elem Res* 2012;150(1-3):42-8. doi: 10.1007/s12011-012-9487-5.